Posts Archive

PROMISE NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population The PROMISE Study aims to...

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma This early phase I trial studies the side effects of...

(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab,...

CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...

NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab The purpose of this study is to test...

RRMM Phase A: Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with...

CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma Study CC-93269-MM-001...

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228) The purpose of this study is to assess...

EVOLVE Autologous BCMA-specific CAR-T cells JCARH125 NCT03430011: Phase 1/2 - Study Evaluating the Safety and Efficacy of JCARH125 in...

KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...

NCT03777410: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma Mass Accumulation Rate (MAR) as a Predictive...

KarMMa-3 bb2121 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma...

NCT03657251: MMRF CureCloud Research Initiative NDMM RRMM MGUS/SMM MMRF CureCloud Research Initiative Observational Study The MMRF...

PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...

NCT03729804: Phase 3: Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in...

NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma The body has different ways of fighting...

NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...